VG H&N course intro Florence 2016.pptx

472-473 / 2351

DAHANCA19: Loco‐regional control
control 77%
zalutumumab 76%
HR: 1.14 [95% CI: 0.81‐1.59]
Pts. at risk Events
zalutumumab. 301 70
control 307 63
total 608 133
Eriksen, H&N Arizona 2014